p.82 抽出テキスト

fibrillation: a meta-analysis of randomised controlled trials. Acta Cardiol 2022;77: 191–5. https://doi.org/10.1080/00015385.2021.1882111 441. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidencebased clinical practice guidelines (8th Edition). Chest 2008;133:257s–98s. https://doi. org/10.1378/chest.08-0674 442. Gallego P, Roldán V, Torregrosa JM, Gálvez J, Valdés M, Vicente V, et al. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2012;5: 312–8. https://doi.org/10.1161/CIRCEP.111.967000 443. Bouillon K, Bertrand M, Boudali L, Ducimetière P, Dray-Spira R, Zureik M. Short-term risk of bleeding during heparin bridging at initiation of vitamin K antagonist therapy in more than 90 000 patients with nonvalvular atrial fibrillation managed in outpatient care. J Am Heart Assoc 2016;5:e004065. https://doi.org/10.1161/JAHA.116.004065 444. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007;167:239–45. https:// doi.org/10.1001/archinte.167.3.239 445. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:2071–104. https://doi.org/10.1161/CIR.0000000000000040 446. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 2011;106:739–49. https://doi.org/10.1160/TH11-05-0364 447. Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2020;76:594–622. https://doi.org/10.1016/j. jacc.2020.04.053 448. Cuker A. Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication. J Thromb Thrombolysis 2016;41:241–7. https://doi.org/10.1007/s11239-015-1282-7 449. Douxfils J, Ageno W, Samama CM, Lessire S, Ten Cate H, Verhamme P, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost 2018;16:209–19. https://doi.org/10.1111/jth.13912 450. Milling TJ, Jr, Refaai MA, Sarode R, Lewis B, Mangione A, Durn BL, et al. Safety of a fourfactor prothrombin complex concentrate versus plasma for vitamin K antagonist reversal: an integrated analysis of two phase IIIb clinical trials. Acad Emerg Med 2016; 23:466–75. https://doi.org/10.1111/acem.12911 451. Pollack CV, Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med 2017;377: 431–41. https://doi.org/10.1056/NEJMoa1707278 452. Connolly SJ, Sharma M, Cohen AT, Demchuk AM, Członkowska A, Lindgren AG, et al. ANNEXA–I investigators. Andexanet for factor Xa inhibitor–associated acute intracerebral hemorrhage. N Engl J Med 2024;390:1745–55. https://doi.org/10.1056/ NEJMoa2313040 453. Milioglou I, Farmakis I, Neudeker M, Hussain Z, Guha A, Giannakoulas G, et al. Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis. J Thromb Thrombolysis 2021;52:1137–50. https://doi.org/10.1007/s11239-021-02480-w 454. Meyre PB, Blum S, Hennings E, Aeschbacher S, Reichlin T, Rodondi N, et al. Bleeding and ischaemic events after first bleed in anticoagulated atrial fibrillation patients: risk and timing. Eur Heart J 2022;43:4899–908. https://doi.org/10.1093/eurheartj/ehac587 455. Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019;380:1326–35. https://doi.org/10.1056/NEJMoa1814051 456. Fanikos J, Murwin D, Gruenenfelder F, Tartakovsky I, França LR, Reilly PA, et al. Global use of idarucizumab in clinical practice: outcomes of the RE-VECTO surveillance program. Thromb Haemost 2020;120:27–35. https://doi.org/10.1055/s-0039-1695771 457. Kotecha D, Calvert M, Deeks JJ, Griffith M, Kirchhof P, Lip GY, et al. A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. BMJ Open 2017;7:e015099. https://doi.org/10.1136/bmjopen-2016-015099 458. Hess PL, Sheng S, Matsouaka R, DeVore AD, Heidenreich PA, Yancy CW, et al. Strict versus lenient versus poor rate control among patients with atrial fibrillation and heart failure (from the get with the guidelines—heart failure program). Am J Cardiol 2020; 125:894–900. https://doi.org/10.1016/j.amjcard.2019.12.025 459. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363–73. https://doi.org/10.1056/NEJMoa1001337 460. Olshansky B, Rosenfeld LE, Warner AL, Solomon AJ, O’Neill G, Sharma A, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004;43:1201–8. https:// doi.org/10.1016/j.jacc.2003.11.032 461. Ulimoen SR, Enger S, Carlson J, Platonov PG, Pripp AH, Abdelnoor M, et al. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol 2013;111: 225–30. https://doi.org/10.1016/j.amjcard.2012.09.020 462. Tisdale JE, Padhi ID, Goldberg AD, Silverman NA, Webb CR, Higgins RS, et al. A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery. Am Heart J 1998;135:739–47. https://doi. org/10.1016/S0002-8703(98)70031-6 463. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003;42:1944–51. https://doi.org/10.1016/j.jacc.2003. 07.020 464. Nikolaidou T, Channer KS. Chronic atrial fibrillation: a systematic review of medical heart rate control management. Postgrad Med J 2009;85:303–12. https://doi.org/10. 1136/pgmj.2008.068908 465. Figulla HR, Gietzen F, Zeymer U, Raiber M, Hegselmann J, Soballa R, et al. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial. Circulation 1996;94:346–52. https://doi.org/10.1161/01.CIR.94.3.346 466. Andrade JG, Roy D, Wyse DG, Tardif JC, Talajic M, Leduc H, et al. Heart rate and adverse outcomes in patients with atrial fibrillation: a combined AFFIRM and AF-CHF substudy. Heart Rhythm 2016;13:54–61. https://doi.org/10.1016/j.hrthm.2015.08.028 467. Weerasooriya R, Davis M, Powell A, Szili-Torok T, Shah C, Whalley D, et al. The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol 2003;41:1697–702. https://doi.org/10.1016/S0735- 1097(03)00338-3 468. Lim KT, Davis MJ, Powell A, Arnolda L, Moulden K, Bulsara M, et al. Ablate and pace strategy for atrial fibrillation: long-term outcome of AIRCRAFT trial. Europace 2007;9: 498–505. https://doi.org/10.1093/europace/eum091 469. Vijayaraman P, Subzposh FA, Naperkowski A. Atrioventricular node ablation and His bundle pacing. Europace 2017;19:iv10–6. https://doi.org/10.1093/europace/eux263 470. Brignole M, Pokushalov E, Pentimalli F, Palmisano P, Chieffo E, Occhetta E, et al. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J 2018;39:3999–4008. https://doi.org/10.1093/eurheartj/ehy555 471. Brignole M, Pentimalli F, Palmisano P, Landolina M, Quartieri F, Occhetta E, et al. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J 2021;42:4731–9. https://doi.org/10.1093/eurheartj/ehab569 472. Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M, Gschwandtner M, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001;29:1149–53. https://doi.org/10.1097/ 00003246-200106000-00011 473. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J 1995;16:521–8. https://doi.org/10.1093/oxfordjournals.eurheartj.a060945 474. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace 2006;8:935–42. https:// doi.org/10.1093/europace/eul106 475. Scheuermeyer FX, Grafstein E, Stenstrom R, Christenson J, Heslop C, Heilbron B, et al. Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness. Acad Emerg Med 2013;20:222–30. https://doi.org/10.1111/acem.12091 476. Siu CW, Lau CP, Lee WL, Lam KF, Tse HF. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. Crit Care Med 2009;37:2174–9, quiz 2180. https://doi.org/10.1097/CCM.0b013e3181a02f56 477. Perrett M, Gohil N, Tica O, Bunting KV, Kotecha D. Efficacy and safety of intravenous beta-blockers in acute atrial fibrillation and flutter is dependent on beta-1 selectivity: a systematic review and meta-analysis of randomised trials. Clin Res Cardiol 2023; 113:831–41. https://doi.org/10.1007/s00392-023-02295-0 478. Darby AE, Dimarco JP. Management of atrial fibrillation in patients with structural heart disease. Circulation 2012;125:945–57. https://doi.org/10.1161/ CIRCULATIONAHA.111.019935 479. Imamura T, Kinugawa K. Novel rate control strategy with landiolol in patients with cardiac dysfunction and atrial fibrillation. ESC Heart Fail 2020;7:2208–13. https://doi.org/ 10.1002/ehf2.12879 480. Ulimoen SR, Enger S, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, et al. Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J 2014;35:517–24. https://doi.org/10.1093/eurheartj/eht429 481. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268–76. https://doi. org/10.1056/NEJMoa1109867

ESC Guidelines                                                                                                                                                                                          3395

Downloaded from academic.oup.com/eurheartj/article/45/36/3314/7738779 by guest on 07 October 2026